Fachbereiche Thoraxchirurgie Forschung

Forschung

Klinische Studien

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN)

Open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with resectable NSCLC stage II/III

  • Primary objective: to assess feasibility and safety of neoadjuvant pembrolizumab and to assess clinical and pathologic tumor response
  • Secondary objective: to assess the impact of neoadjuvant pembrolizumab on patient disease free and overall survival.
  • Exploratory objective: to explore potential predictive biomarkers for pembrolizumab efficacy (immune cell imaging)

Contact: OA PD Dr. Martin Eichhorn / OA Dr. Florian Eichhorn

Status: Active, not recruiting

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NIVOLUMAB WITH CHEMOTHERAPY IN PLEURAL MESOTHELIOMA AFTER SURGERY (NIKITA)

Open-label, multicenter, randomized (1:1), controlled study including patients with malignant pleural mesothelioma (MPM) in tumor stages I-III who have previously undergone cytoreductive surgery by extended pleurectomy/decortication with or without hyperthermic intrathoracic chemoperfusion (eP/D ± HITOC). Primary objective: time to next treatment, feasibility and safety. Tumor tissue, blood and stool samples will

  • Arm A: platinum-based adjuvant chemotherapy q4w be collected for accompanying research project
  • Arm B: platinum-based adjuvant chemotherapy q4w together with up to 12 cycles (q4w) maintenance immunotherapy with nivolumab iv (480mg fixed dose

Contact: OA PD Dr. Martin Eichhorn / OÄ Dr. Laura Klotz

Status: Recruiting

 

 

 

 

 

Publikationen 2020

  1. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.  Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. EMBO J. 2020 May 18;39(10):e105114. doi: 10.15252/embj.20105114. Epub 2020 Apr 14. PMID: 32246845
  2. Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.  Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS, Huber M, Savai R. J Clin Invest. 2020 Jul 1;130(7):3560-3575. doi: 10.1172/JCI124037. PMID: 32229721
  3. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. Zheng X, Weigert A, Reu S, Guenther S, Mansouri S, Bassaly B, Gattenlöhner S, Grimminger F, Pullamsetti S, Seeger W, Winter H, Savai R. Cancer Res. 2020 Oct 15;80(20):4414-4425. doi: 10.1158/0008-5472.CAN-20-0069. Epub 2020 Jul 22. PMID: 32699134
  4. Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Rheinheimer S, Heussel CP, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H, Herth FJ, Muley T, Liersch S, Bischoff H, Kriegsmann M, El Shafie RA, Stenzinger A, Thomas M, Kauczor HU, Christopoulos P. Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046. PMID: 32340408
  5. A solid-phase transfection platform for arrayed CRISPR screens.  Serçin Ö, Reither S, Roidos P, Ballin N, Palikyras S, Baginska A, Rein K, Llamazares M, Halavatyi A, Winter H, Muley T, Jurkowska RZ, Abdollahi A, Zenke FT, Neumann B, Mardin BR. Mol Syst Biol. 2020 Jun;16(6):e9611. doi: 10.15252/msb.209611. PMID: 33438803
  6. Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. Wessels S, Muley T, Christopoulos P, Meister M, Heinzmann-Groth I, Warth A, Herpel E, Hummler S, Klingmüller U, Kuon J, Heussel CP, Eberhardt R, Herth FJF, Winter H, Bischoff H, Stenzinger A, Reck M, Huber RM, Thomas M, Schneider MA. Transl Lung Cancer Res. 2020 Aug;9(4):1000-1014. doi: 10.21037/tlcr-20-137. PMID: 32953480
  7. Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. Turkowski K, Herzberg F, Günther S, Brunn D, Weigert A, Meister M, Muley T, Kriegsmann M, Schneider MA, Winter H, Thomas M, Grimminger F, Seeger W, Savai Pullamsetti S, Savai R. Cells. 2020 Jul 22;9(8):1755. doi: 10.3390/cells9081755. PMID: 32707902
  8. Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes.  Kriegsmann M, Zgorzelski C, Casadonte R, Schwamborn K, Muley T, Winter H, Eichhorn M, Eichhorn F, Warth A, Deininger SO, Christopoulos P, Thomas M, Longerich T, Stenzinger A, Weichert W, Müller-Tidow C, Kriegsmann J, Schirmacher P, Kriegsmann K. Cancers (Basel). 2020 Sep 21;12(9):2704. doi: 10.3390/cancers12092704.
  9. Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Regnery S, Eichkorn T, Weykamp F, Held T, Weusthof K, Dinges LA, El-Shafie RA, Winter H, Thomas M, Debus J, Adeberg S, Hörner-Rieber J. Clin Lung Cancer. 2020 Nov 18:S1525-7304(20)30336-3. doi: 10.1016/j.cllc.2020.11.003. Online ahead of print. PMID: 33281061
  10. Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors.  Regnery S, Eichkorn T, Weykamp F, Held T, Dinges LA, Schunn F, Winter H, Thomas M, Debus J, El Shafie RA, Adeberg S, Hörner-Rieber J. Cancers (Basel). 2020 Oct 5;12(10):2862. doi: 10.3390/cancers12102862. PMID: 33027940
  11. An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices. Khan MM, Poeckel D, Halavatyi A, Zukowska-Kasprzyk J, Stein F, Vappiani J, Sevin DC, Tischer C, Zinn N, Eley JD, Gudmann NS, Muley T, Winter H, Fisher AJ, Nanthakumar CB, Bergamini G, Pepperkok R. Eur Respir J. 2020 Dec 24:2000221. doi: 10.1183/13993003.00221-2020. Online ahead of print. PMID: 33361096
  12. Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.  Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H, Longuespée R, Kriegsmann J, Warth A, Kriegsmann M. Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):237-242. doi: 10.1097/PAI.0000000000000715. PMID: 30358615
  13. Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis.  Küster MM, Schneider MA, Richter AM, Richtmann S, Winter H, Kriegsmann M, Pullamsetti SS, Stiewe T, Savai R, Muley T, Dammann RH. Cancers (Basel). 2020 Nov 26;12(12):3528. doi: 10.3390/cancers12123528. PMID: 33256112
  14. Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany.  Markowiak T, Koller M, Zeman F, Huppertz G, Hofmann HS, Ried M; HITOC Study Group. BMJ Open. 2020 Jul 20;10(7):e041511. doi: 10.1136/bmjopen-2020-041511. PMID: 32690754
  15. Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer.  Safi S, Yamauchi Y, Hoffmann H, Weichert W, Jost PJ, Winter H, Muley T, Beckhove P. Cancers (Basel). 2020 Nov 24;12(12):3496. doi: 10.3390/cancers12123496. PMID: 33255425
  16. Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer.  Kriegsmann K, Zgorzelski C, Muley T, Christopoulos P, von Winterfeld M, Herpel E, Goeppert B, Mechtersheimer G, Sinn P, Stenzinger A, Schirmacher P, Winter H, Eichinger M, Warth A, Kriegsmann M. Histopathology. 2020 Dec;77(6):900-914. doi: 10.1111/his.14203. Epub 2020 Oct 11. PMID: 32634256
  17. Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1.  Koelsche C, Tavernar L, Neumann O, Heußel CP, Eberhardt R, Winter H, Stenzinger A, Mechtersheimer G. Virchows Arch. 2020 May;476(5):787-791. doi: 10.1007/s00428-019-02716-4. Epub 2019 Nov 27. PMID: 31776646
  18. Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer.  Kriegsmann M, Haag C, Weis CA, Steinbuss G, Warth A, Zgorzelski C, Muley T, Winter H, Eichhorn ME, Eichhorn F, Kriegsmann J, Christopoulos P, Thomas M, Witzens-Harig M, Sinn P, von Winterfeld M, Heussel CP, Herth FJF, Klauschen F, Stenzinger A, Kriegsmann K. Cancers (Basel). 2020 Jun 17;12(6):1604. doi: 10.3390/cancers12061604.
  19. Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.  Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M. Lung Cancer. 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007. Epub 2020 Aug 22. PMID: 32871455
  20. [Expert Recommendation for the Implementation of Hyperthermic Intrathoracic Chemotherapy (HITOC) in Germany]. Ried M, Eichhorn M, Winter H, Grützner U, Lindner M, Hatz RA, Haager B, Passlick B, Galetin T, Lopez-Pastorini A, Stoelben E, Hofmann HS. Zentralbl Chir. 2020 Feb;145(1):89-98. doi: 10.1055/a-0934-7806. Epub 2019 Jul 10. PMID: 31291667 German.
  21. Consolidating Lung Volume Reduction Surgery After Endoscopic Lung Volume Reduction Failure.  Eichhorn ME, Gompelmann D, Hoffmann H, Dreher S, Hornemann K, Haag J, Kontogianni K, Heussel CP, Winter H, Herth FJF, Eberhardt R. Ann Thorac Surg. 2020 Sep 28:S0003-4975(20)31551-4. doi: 10.1016/j.athoracsur.2020.06.148. Online ahead of print. PMID: 32991839
  22. Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Shah R, Klotz LV, Chung I, Feißt M, Schneider MA, Riedel J, Bischoff H, Eichhorn ME, Thomas MA. Clin Lung Cancer. 2020 Oct 14:S1525-7304(20)30307-7. doi: 10.1016/j.cllc.2020.10.005.
  23. Mortality and complication management after surgery for colorectal cancer depending on the DKG minimum amounts for hospital volume. Diers J, Baum P, Matthes H, Germer CT, Wiegering A. Eur J Surg Oncol. 2021 Apr;47(4):850-857. doi: 10.1016/j.ejso.2020.09.024. Epub 2020 Sep 25. PMID: 33020007.
  24. Lokaltherapie solitärer intrapulmonaler maligner Rundherde. Op den Winkel J, Eichhorn F, Fischer LA, Rieken S, Winter H. Pneumologe 17, 489–498 (2020).
  25. Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany. Baum P, Diers J, Haag J, Klotz L, Eichhorn F, Eichhorn M, Wiegering A, Winter H. Lung Cancer. 2020 Nov;149:78-83. doi: 10.1016/j.lungcan.2020.08.018. Epub 2020 Aug 31.
  26. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer.  Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, Kirchner M, Charoentong P, Volk N, Haag J, Wirtz R, Oskarsson T, Schulz A, Heil J, Schneeweiss A, Winter H, Sinn P. JCO Precis Oncol. 2020 Jul 24;4:PO.19.00337. doi: 10.1200/PO.19.00337. eCollection 2020. PMID: 32923902